{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:36:51Z","timestamp":1787017011092,"version":"build-2736575974"},"reference-count":32,"publisher":"Wiley","issue":"20","license":[{"start":{"date-parts":[[2016,11,19]],"date-time":"2016-11-19T00:00:00Z","timestamp":1479513600000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Record"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:p>The aim of the study was to evaluate the incidence of adverse events (AEs) in female dogs diagnosed with advanced clinical stage mammary gland neoplasms following treatment with thalidomide. A prospective analysis of 29 female dogs treated with a high dose (HD) of 20\u00a0mg\/kg\/day of thalidomide for three months followed by a low dose (LD) of 10\u00a0mg\/kg\/day of thalidomide for three months was performed. All patients underwent physical examination, complete blood count, serum biochemistry profile, thoracic radiographs, and abdominal ultrasound analysis before the treatment and after the HD and LD. Clinical AEs were absent in 16\/29 (55.17 per cent) patients following HD. An initial 3\u20135\u00a0day period of somnolence was described in 4\/29 (13.79 per cent), prolonged somnolence in 5\/29 (17.24 per cent), a short period of somnolence lasting only a few hours in 3\/29 (10.34 per cent), and difficulty to rouse was described in 5\/29 (17.24 per cent) cases. Two patients (6.89 per cent) presented with prolonged somnolence that interfered with activities of daily living, resulting in anticipation of the dose reduction to the proposed LD after 15\u00a0days of the HD treatment. Following dose reduction, AE improvement was observed in all patients. Albeit remaining within the reference ranges, erythrocytes, haematocrit, total leucocyte count, neutrophils, lymphocytes, monocytes and \u03b3\u2010glutamyltranspeptidase showed significant alteration associated to thalidomide treatment.<\/jats:p>","DOI":"10.1136\/vr.103764","type":"journal-article","created":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T22:39:35Z","timestamp":1471991975000},"page":"514-514","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Absence of significant adverse events following thalidomide administration in bitches diagnosed with mammary gland carcinomas"],"prefix":"10.1002","volume":"179","author":[{"given":"C. B.","family":"de Campos","sequence":"first","affiliation":[{"name":"Department of Veterinary Clinic and Surgery School of Agricultural and Veterinary Sciences of the Sao Paulo State University (FCAV\/UNESP) \u2013 Jaboticabal Campus Jaboticabal Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. E.","family":"Lavalle","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinic and Surgery Veterinary School, Federal University of Minas Gerais (UFMG) Belo Horizonte Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Fialho Lig\u00f3rio","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Biotechnological Development Funda\u00e7\u00e3o Ezequiel Dias Belo Horizonte Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Camargo Nunes","sequence":"additional","affiliation":[{"name":"Laboratory of Comparative Pathology Department of General Pathology Federal University of Minas Gerais (UFMG) Belo Horizonte Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. A.","family":"Carneiro","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinic and Surgery Veterinary School, Federal University of Minas Gerais (UFMG) Belo Horizonte Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. L.","family":"Amorim","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinics College of Veterinary Medicine and Animal Science, Sao Paulo State University (FMVZ\/UNESP) \u2013 Botucatu Campus Botucatu Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. D.","family":"Cassali","sequence":"additional","affiliation":[{"name":"Laboratory of Comparative Pathology Department of General Pathology Federal University of Minas Gerais (UFMG) Belo Horizonte Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,19]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"61","article-title":"Canine mammary gland neoplasms","volume":"19","author":"BRODEY R. S.","year":"1983","journal-title":"Journal of the American Animal Hospital Association"},{"key":"e_1_2_6_3_1","first-page":"38","article-title":"Consensus for the diagnosis, prognosis and treatment of canine mammary tumors \u2013 2013","volume":"7","author":"CASSALI G.","year":"2014","journal-title":"Brazilian Journal of Veterinary Pathology"},{"key":"e_1_2_6_4_1","unstructured":"CELGENE(2015)Thalidomid REMS.http:\/\/www.thalomidrems.com\/. Accessed October 5 2016"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.2874"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2013.08.004"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70068-1"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.03.040"},{"key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1590\/S1676-24442014000100009","article-title":"Thalidomide promotes leukocytosis in mice inoculated with 4T1\u00a0mammary carcinoma","volume":"50","author":"DOS REIS D.","year":"2014","journal-title":"Journal Brasileiro de Patologia e Medicina Laboratorial"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf213"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5217.1954"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1177319"},{"key":"e_1_2_6_13_1","unstructured":"JANKOWSKI M. FULTON L. SHEAFOR S. PRESCOTT D.&KHANNA C.(1999)Ongoing evaluation of single agent thalidomide in dogs with measurable cancer.In Veterinary Cancer Society 19th Annual Meeting"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0442.2001.00336.x"},{"key":"e_1_2_6_15_1","first-page":"67","volume-title":"BSAVA Manual of canine and feline oncology","author":"LANA S. E.","year":"2011"},{"key":"e_1_2_6_16_1","first-page":"375","article-title":"Canine malignant mammary gland neoplasms with advanced clinical staging treated with carboplatin and cyclooxygenase inhibitors","volume":"26","author":"LAVALLE G. E.","year":"2012","journal-title":"Vivo"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420380303"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2012.04.005"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2011.00304.x"},{"key":"e_1_2_6_20_1","first-page":"1358","article-title":"Thalidomide and congenital abnormalities","volume":"278","author":"MCBRIDE W. G.","year":"1961","journal-title":"Public Health"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420160113"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/svms.2003.36625"},{"key":"e_1_2_6_23_1","volume-title":"TNM Classification of Tumors in Domestic Animals","author":"OWEN L. N.","year":"1980"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0753-3322(01)00146-9"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-5616(03)00020-2"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4377-2362-5.00027-X"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000077043"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1249543"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1191\/096032700673027800"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443050-00004"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/59.1.160"},{"key":"e_1_2_6_32_1","first-page":"194","article-title":"Veterinary cooperative oncology group \u2013 common terminology criteria for adverse events (VCOG\u2010CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1","volume":"2","author":"VETERINARY CO\u2010OPERATIVE ONCOLOGY GROUP","year":"2004","journal-title":"Veterinary and Comparative Oncology"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5810.2004.0045p.x"}],"container-title":["Veterinary Record"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1136%2Fvr.103764","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bvajournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1136\/vr.103764","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:13:49Z","timestamp":1761567229000},"score":1,"resource":{"primary":{"URL":"https:\/\/bvajournals.onlinelibrary.wiley.com\/doi\/10.1136\/vr.103764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":32,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1136\/vr.103764"],"URL":"https:\/\/doi.org\/10.1136\/vr.103764","archive":["Portico"],"relation":{},"ISSN":["0042-4900","2042-7670"],"issn-type":[{"value":"0042-4900","type":"print"},{"value":"2042-7670","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}